腺病毒5型载体与灭活新冠疫苗对B.1.617.2(Delta)变异株所致有症状COVID-19、肺炎及重症的保护效果:2021年中国云南疫情证据
2021年云南瑞丽Delta变异株暴发中,纳入686名≥18岁中国籍密切接触者进行回顾性队列研究,评估腺病毒5型载体疫苗和两种灭活疫苗对有症状COVID-19、肺炎及重症的保护效果。三种疫苗对重症均有保护,对肺炎和有症状感染亦有保护,疫苗间差异无统计学意义;全程接种者RT-PCR阳性持续时间中位数短于未接种者。
要点
- 腺病毒5型载体疫苗对有症状COVID-19调整VE为61.5%(95%CI 9.5-83.6),对肺炎67.9%(95%CI 1.7-89.9),对重症/危重症100%(95%CI 36.6-100)。
- 两种灭活疫苗合并对有症状COVID-19调整VE为74.6%(95%CI 36.0-90.0),对肺炎76.7%(95%CI 19.3-93.3),对重症/危重症100%(95%CI 47.6-100)。
- RT-PCR阳性持续时间中位数:灭活疫苗组17天(15人),腺病毒5型载体疫苗组18天(44人),未接种组26天(11人)。
核心结论
- 三种疫苗在接种运动后短期内有助预防Delta变异株所致COVID-19,对较重疾病保护效果最高;全程接种者RT-PCR阳性持续时间缩短,提示可能节约医疗资源。
研究设计与样本
- 回顾性队列研究,纳入瑞丽疫苗接种运动后约2个月(中位63天)的686名≥18岁中国籍密切接触者,比较未接种与全程接种者结局,采用logistic回归调整性别和年龄组(18-59岁与≥60岁)估计疫苗效果。
主要发现
- 腺病毒5型载体疫苗对有症状COVID-19调整VE为61.5%(95%CI 9.5-83.6),对肺炎67.9%(95%CI 1.7-89.9),对重症/危重症100%(95%CI 36.6-100)。
- 两种灭活疫苗合并对有症状COVID-19调整VE为74.6%(95%CI 36.0-90.0),对肺炎76.7%(95%CI 19.3-93.3),对重症/危重症100%(95%CI 47.6-100)。
- 两种灭活疫苗之间对有症状COVID-19和肺炎的VE差异无统计学意义,灭活疫苗与腺病毒5型载体疫苗在三种结局上的VE差异均无统计学意义。
- RT-PCR阳性持续时间中位数:灭活疫苗组17天(15人),腺病毒5型载体疫苗组18天(44人),未接种组26天(11人)。
关键数值与推荐
- 有症状COVID-19:腺病毒5型载体疫苗调整VE 61.5%(95%CI 9.5-83.6),灭活疫苗合并调整VE 74.6%(95%CI 36.0-90.0)。
- COVID-19肺炎:腺病毒5型载体疫苗调整VE 67.9%(95%CI 1.7-89.9),灭活疫苗合并调整VE 76.7%(95%CI 19.3-93.3)。
- 重症/危重症COVID-19:腺病毒5型载体疫苗调整VE 100%(95%CI 36.6-100),灭活疫苗合并调整VE 100%(95%CI 47.6-100)。
临床怎么用
- 原文结论认为三种疫苗在接种运动后短期内有助预防Delta变异株COVID-19,对较重疾病保护效果最高。
- 原文指出全程接种与RT-PCR阳性持续时间及住院时间缩短相关,提示可能节约医疗资源。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In partial response to the coronavirus disease 2019 (COVID-19) pandemic, countries around the world are conducting large-scale vaccination campaigns. Real-world estimates of vaccine effectiveness (VE) against the B.1.617.2 (Delta) variant are still limited. An outbreak in Ruili city of Chinaprovided an opportunity to evaluate VE against the Delta variant of two types of COVID-19 vaccines in use in China and globally - inactivated (CoronaVac and BBIBP-CorV) and adenovirus type 5 vectored (Convidecia) vaccines. METHODS: We estimated VE using a retrospective cohort study two months after the Ruili vaccination campaign (median: 63 days). Close contacts of infected people (Chinese nationality, 18 years and above) were included to assess VE against symptomatic Covid-19, COVID-19 pneumonia, and severe COVID-19. We calculated the relative risks (RR) of the outcomes for unvaccinated compared with fully vaccinated individuals. We used logistic regression analyses to estimate adjusted VEs, controlling for gender and age group (18-59 years and 60 years and over).We compared unvaccinated and fully vaccinated individuals on duration of RT-PCR positivity and Ct value. FINDINGS: There were 686 close contacts eligible for VE estimates. Adjusted VE ofad5-vectored vaccine was 61.5% (95% CI, 9.5-83.6) against symptomatic COVID-19, 67.9% (95%CI: 1.7-89.9) against pneumonia, and 100% (95%CI: 36.6-100) against severe/critical illness. For the two inactivated vaccines, combined VE was 74.6% (95% CI, 36.0-90.0) against symptomatic COVID-19, 76.7% (95% CI: 19.3-93.3) against pneumonia, and 100% (95% CI: 47.6-100) against severe/critical COVID-19. There were no statistically significant differences in VE between twoinactivated vaccines for symptomatic COVID-19 and for pneumonia, nor were there statistically significant differences between inactivated and ad5-vectored VE in any of the three outcomes. The median durations of RT-PCR positivity were 17 days for fifteen people vaccinated with an inactivated vaccine, 18 days for forty-four people vaccinated with the Ad5 vectored vaccine, and 26 days for eleven unvaccinated individuals. INTERPRETATION: These results provide reassuring evidence that the three vaccines are effective at preventing Delta-variant COVID-19 in short term following vaccination campaign, and are most effective at preventing more serious illness. The findings of reduced duration of RT-PCR positivity and length of hospital stay associated with full vaccination suggests potential saving of health-care system resources.
引用
- Ma C, Sun W, Tang T, et al. Effectiveness of adenovirus type 5 vectored and inactivated COVID-19 vaccines against symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the B.1.617.2 (Delta) variant: Evidence from an outbreak in Yunnan, China, 2021. Vaccine. 2022. PMID: 35400561. doi:10.1016/j.vaccine.2022.03.067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。